WallStSmart

Bio-Rad Laboratories Inc (BIO)vsGE HealthCare Technologies Inc. (GEHC)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

GE HealthCare Technologies Inc. generates 698% more annual revenue ($20.63B vs $2.58B). BIO leads profitability with a 29.4% profit margin vs 10.1%. BIO appears more attractively valued with a PEG of 1.19. GEHC earns a higher WallStSmart Score of 60/100 (C+).

BIO

Buy

60

out of 100

Grade: C

Growth: 2.7Profit: 6.5Value: 7.3Quality: 8.5
Piotroski: 3/9Altman Z: 3.11

GEHC

Buy

60

out of 100

Grade: C+

Growth: 4.0Profit: 7.0Value: 7.3Quality: 4.3
Piotroski: 2/9Altman Z: 1.34
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

BIOSignificantly Overvalued (-55.1%)

Margin of Safety

-55.1%

Fair Value

$189.38

Current Price

$264.49

$75.11 premium

UndervaluedFair: $189.38Overvalued
GEHCSignificantly Overvalued (-156.0%)

Margin of Safety

-156.0%

Fair Value

$30.94

Current Price

$69.65

$38.71 premium

UndervaluedFair: $30.94Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

BIO5 strengths · Avg: 9.6/10
P/E RatioValuation
9.5x10/10

Attractively priced relative to earnings

Price/BookValuation
1.0x10/10

Reasonable price relative to book value

Altman Z-ScoreHealth
3.1110/10

Safe zone — low bankruptcy risk

Profit MarginProfitability
29.4%9/10

Keeps 29 of every $100 in revenue as profit

Debt/EquityHealth
0.219/10

Conservative balance sheet, low leverage

GEHC2 strengths · Avg: 8.5/10
Return on EquityProfitability
22.4%9/10

Every $100 of equity generates 22 in profit

P/E RatioValuation
15.3x8/10

Attractively priced relative to earnings

Areas to Watch

BIO3 concerns · Avg: 3.0/10
Revenue GrowthGrowth
3.9%4/10

3.9% revenue growth

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

EPS GrowthGrowth
-83.0%2/10

Earnings declined 83.0%

GEHC4 concerns · Avg: 2.8/10
PEG RatioValuation
1.664/10

Expensive relative to growth rate

Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

EPS GrowthGrowth
-17.7%2/10

Earnings declined 17.7%

Altman Z-ScoreHealth
1.342/10

Distress zone — elevated risk

Comparative Analysis Report

WallStSmart Research

Bull Case : BIO

The strongest argument for BIO centers on P/E Ratio, Price/Book, Altman Z-Score. Profitability is solid with margins at 29.4% and operating margin at 8.9%. PEG of 1.19 suggests the stock is reasonably priced for its growth.

Bull Case : GEHC

The strongest argument for GEHC centers on Return on Equity, P/E Ratio.

Bear Case : BIO

The primary concerns for BIO are Revenue Growth, Piotroski F-Score, EPS Growth.

Bear Case : GEHC

The primary concerns for GEHC are PEG Ratio, Piotroski F-Score, EPS Growth.

Key Dynamics to Monitor

BIO carries more volatility with a beta of 1.20 — expect wider price swings.

GEHC is growing revenue faster at 7.1% — sustainability is the question.

GEHC generates stronger free cash flow (917M), providing more financial flexibility.

Monitor MEDICAL DEVICES industry trends, competitive dynamics, and regulatory changes.

Bottom Line

BIO scores higher overall (60/100 vs 60/100), backed by strong 29.4% margins. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Bio-Rad Laboratories Inc

HEALTHCARE · MEDICAL DEVICES · USA

Bio-Rad Laboratories, Inc. is an American developer and manufacturer of specialized technological products for the life science research and clinical diagnostics markets.

Visit Website →

GE HealthCare Technologies Inc.

HEALTHCARE · MEDICAL DEVICES · USA

GE HealthCare Technologies Inc. provides medical technology, pharmaceutical diagnostics, and digital solutions in the United States. The company is headquartered in Chicago, Illinois.

Want to dig deeper into these stocks?